Epidemiological Situation of Dengue in the Americas Region

February 8, 2025

The Pan American Health Organization (PAHO) and the World Health Organization (WHO) have issued an epidemiological alert due to the increased circulation of the DENV-3 serotype in the Americas Region, which may raise the risk of outbreaks and severe cases. Countries are advised to prepare for a higher healthcare burden during the peak dengue season, focusing on early diagnosis and timely treatment.

Historic Increase in Cases in 2024

A total of 13,027,747 dengue cases were reported across 50 countries, including 6,906,396 confirmed cases, 22,684 severe dengue cases, and 8,186 deaths (case fatality rate: 0.063%).

Most Affected Countries in 2024
  • Brazil: 10,232,872 cases
  • Argentina: 581,559 cases
  • Mexico: 558,846 cases
  • Colombia: 320,982 cases
  • Paraguay: 295,785 cases
2025 Data (Epidemiological Weeks 1–4)

A total of 238,659 dengue cases were reported across 23 countries. Six countries accounted for 98% of the cases:

  • Brazil (87%)
  • Colombia (5.6%)
  • Nicaragua (2.5%)
  • Peru (2.5%)
  • Mexico (2.5%)

Additionally, 57,899 cases were confirmed by laboratory testing, with 263 severe dengue cases and 23 deaths (case fatality rate: 0.010%).

Circulation of All Four Dengue Serotypes

DENV-1, DENV-2, DENV-3, and DENV-4 have been simultaneously detected in Brazil, Costa Rica, El Salvador, Mexico, and Panama.


Risk Associated with the Increased Circulation of DENV-3
Historical Epidemiology
  • In 1994, DENV-3 was reintroduced to the Americas after 16 years of absence.
  • Between 2000–2007, it became one of the most frequently detected serotypes in the region, triggering major outbreaks in Brazil, Central America, and the Caribbean.
  • Since 2023, several countries have documented the reemergence and spread of DENV-3, increasing the risk of severe cases.

Situation in 2024–2025
  • Argentina: Circulation of a new DENV-3 genotype in Entre Ríos.
  • Brazil: Reemergence of DENV-3 after several years of low circulation.
  • Colombia: Severe cases reported in the Casanare region.
  • Costa Rica: DENV-3 prevalence rose from 25% in 2023 to 56% in 2024.
  • Guatemala: DENV-3 accounted for 83% of serotyped cases in 2024.
  • Mexico: DENV-3 circulation surged from 6% in 2021 to 86% in 2024.
  • Nicaragua: Historically, DENV-3 has been linked to higher severity.
  • Peru: DENV-3 detected in multiple regions in 2024.
  • Puerto Rico: Since 2023, DENV-3 has displaced DENV-1 as the predominant serotype.

Public Health Implications
  • Increased susceptibility among populations due to prior lack of exposure to the serotype, potentially leading to more severe cases.
  • DENV-3 is considered one of the most virulent serotypes, heightening the risk of hospitalization and severe complications.
  • Health system overload if outbreaks are not adequately controlled.

Share on social

Facebook
Twitter
LinkedIn